Qianjinweijing Decoction Protects Against Fine Particulate Matter Exposure-mediated Lung Function Disorder

Rucheng Chen1,2, Jinna Zhang1, Yaxian Pang3, Qingping Liu3, Jing Peng1, Xiujuan Lin1, Lingyong Cao4, Weijia Gu1,2, Lu Zhang1,2, Ran Li1,2, Qinghua Sun1,2, Rong Zhang3* and Cuiqing Liu1,2*

1School of Public Health, Joint China-US Research Center for Environment and Pulmonary Diseases, Zhejiang Chinese Medical University, Hangzhou, China, 2Zhejiang International Science and Technology Cooperation Base of Air Pollution and Health, Hangzhou, China, 3School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, 4Department of Toxicology, Hebei Medical University, Shijiazhuang, China

Fine particulate matter (PM2.5) is well known to impair lung function. Strategies protecting against PM2.5-exerted lung dysfunction have been less investigated. Qianjinweijing decoction (QJWJ), a decoction of a herbal medicine of natural origin, has been used to treat lung disorders as it inhibits oxidation and inflammation. However, no clinical trial has yet evaluated the role of QJWJ in PM2.5-induced lung dysfunction. Therefore, we conducted a randomized, double-blind, placebo-controlled trial to assess whether QJWJ provided lung benefits against the adverse effects of PM2.5 exposure among adults. Eligible participants (n = 65) were recruited and randomized to receive QJWJ decoction (n = 32) or placebo (n = 33) for 4 weeks. The restrictive ventilatory defect (RVD), lung function parameters, and induced sputum were analyzed. The PM2.5 exposure concentration was significantly associated with the vital capacity (VC), peak expiratory flow (PEF), and forced expiratory flow at 75% of the forced vital capacity (FEF75). The negative associations between PM2.5 and the lung function parameters were eliminated in response to the QJWJ intervention. Additionally, the percentage of RVD (P = 0.018) and the proportion of eosinophils (Eo%) in induced sputum (P = 0.014) in the QJWJ group was significantly lower than that in the placebo group. This study demonstrated that QJWJ could alleviated PM2.5-induced lung dysfunction and could be a potential treatment for air pollution-related chronic respiratory disease.

Keywords: fine particulate matter, lung function, traditional Chinese medicine, qianjinweijing decoction, restrictive ventilatory defect (RVD)

Clinical Trial Registration: www.chictr.org.cn, identifier ChiCTR2000039210.

INTRODUCTION

Chronic respiratory disease, a category of chronic non-communicable disease, is one of the leading causes of death across all age groups and both sexes worldwide. According to the Global Burden of Disease, chronic respiratory disease accounts for 2.92 million (11.3%) and 3.75 million (12.2%)
deaths in females and males, respectively (GBD Chronic Respiratory Disease Collaborators, 2020). Lung function decline is an important marker of most common chronic respiratory disease, including chronic obstructive pulmonary disease, chronic bronchitis, and asthma (GBD Risk Factor Collaborators, 2018). The restrictive ventilatory defect (RVD) is one of the key markers of lung function decline. The Burden of Obstructive Lung Disease (BOLD) study has shown that the incidence of RVD varies widely across different countries, ranging from less than 10% to more than 40% (Lee et al., 2015; Godfrey and Jankowich, 2016). A previous study indicated that RVD is also associated with the morbidity and mortality of cardiovascular disease, diabetes, and other diseases (Duprez and Jacobs, 2018). Given the crucial role of lung function, improving lung function over time in populations is particularly important.

Ambient fine particulate matter (PM$_{2.5}$) is a risk factor for respiratory disease, contributing to 1.4 million deaths (GBD Risk Factor Collaborators, 2018). PM$_{2.5}$ may accumulate in the lung and cause cumulative damage in the respiratory system (Falcon-Rodriguez et al., 2016). Numerous studies have reported that PM$_{2.5}$ pollution leads to reductions in various lung function parameters, including the forced vital capacity (FVC), forced expiratory volume in 1s (FEV$_{1.0}$), and maximal mid-expiratory flow (MMEF) (Hwang et al., 2015; Xu et al., 2018; Guo et al., 2019). Interventions, such as particulate-filtering respirators or masks, could improve PM$_{2.5}$-related lung function decline and the prevent substantial morbidity, disability, and risk of death associated with the exacerbation of respiratory disease (Chen et al., 2015; Lin et al., 2019; Pacitto et al., 2020). However, these interventions are not portable or readily available on some occasions, e.g., outdoors and during social interactions. Therefore, effective interventions attenuating PM$_{2.5}$’s hazardous effects on health are urgent and necessary.

Studies have indicated that inflammation, oxidative stress, and pulmonary fibrosis are critical pathways in lung function decline following exposure to PM$_{2.5}$ (Ni et al., 2015; Xing et al., 2016). Thus, interventions targeting these biological pathways may offer lung benefits against the adverse effects of PM$_{2.5}$ exposure. Due to the anti-inflammatory and antioxidant function of natural supplements, Chinese herbs may provide preventive benefits for PM$_{2.5}$-related lung injury. The Qianjinweijing decoction (QJWJ) contains four types of edible herbs: Phragmites australis (Cav.) Trin. ex Steud. [Poaceae], Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf [Poaceae], Prunus persica (L.) Batsch [Rosaceae], and Benincasa hispida (Thunb.) Cogn [Cucurbitaceae]. This decoction was prescribed for “Feiyong” (pulmonary abscess) recorded in the traditional Chinese medicine classics of Jin Gui Yao Lue and Qian Jin Yao Fang more than 1,000 years ago (Liu et al., 2014). Previous studies have indicated that QJWJ attenuates inflammation, oxidative stress, and regulates pulmonary immunity (Liu et al., 2014). Clinically, QJWJ was typically used as an adjuvant medicine to improve lung function and quality of life because of its natural origin and relatively fewer side effects (Liu et al., 2017). However, it was not known whether QJWJ could protect against PM$_{2.5}$-induced lung damage in humans. Therefore, we conducted a randomized, double-blinded, placebo-controlled trial to assess whether QJWJ offered lung benefits against PM$_{2.5}$ pollution-related damage in adults.

**METHODS**

**Participants**

This trial was conducted between November 2020 and December 2020 at Hebei Medical University, Shijiazhuang, China. Our pre-study result showed an 11% difference in FVC between groups. To detect this difference with 90% power at a significance level (alpha) of 0.05 required 58 participants. All participants were randomly divided into the QJWJ and placebo groups. All participants took QJWJ or placebo twice daily for 4 weeks from November 21 to 20 December 2020. We conducted one baseline examination and two rounds of follow-up visits, with intervals of 2 weeks. At baseline and follow-up, we collected fasting blood samples and measured RVD, lung function, heart rate, respiration rate, and blood pressure. At the end of the trial, the induced sputum was tested for inflammatory cells. Additionally, individual characteristics (height and weight) were recorded at baseline and follow-up. Volunteers, researchers, and data collection staff were blinded to the allocation.

This study was approved by the Ethics Committee of Hebei Medical University and registered in the Chinese Clinical Trial Registry (ChiCTR2000039210). All participants provided written informed consent on enrollment.

**Interventions**

The QJWJ and placebo granules were produced by Zhejiang Yalin Biological Technology Co., Ltd. China. The QJWJ granules contained four medicinal herbs extracted and purified from 12 g of Phragmites australis (Cav.) Trin. ex Steud [Poaceae], 6 g of Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf [Poaceae], 4.5 g of Prunus persica (L.) Batsch [Rosaceae], and 6 g of Benincasa hispida (Thunb.) Cogn [Cucurbitaceae]. In contrast, the placebo was composed of dextrin and caramel and was identical to QJWJ in color, shape, size, and packaging. Participants were instructed to take two packages of QJWJ, or placebo, dissolved in water per day throughout the study period. They were also asked to complete two questionnaires to determine compliance, on the day before both follow-ups. Meanwhile, the staff created several instant
UPLC-Q-TOF/MS Analysis

QJWJ granules were dissolved in purified water at the concentration of 100 mg/ml. The solution was then centrifuged for the supernatant. The UPLC analyses of QJWJ solution supernatant was performed using the 2.1 × 100 mm reversed-phase C18 analytical columns with 1.6 μm silica-based (Cortecs® UPLC® T3, waters, SYNAPT G2-Si, US). The mobile phase was composed of solvent A 10% (formic acid at 0.1%) and solvent B 90% (acetonitrile). The injection volume was 2 µl in each run with a flow rate of 0.3 ml/min and a gradient elution of 35 min: 0–2 min, 5% B; 2–32 min, 5–100% B; 32–33 min, 100% B; 33–35, 5% B. MS spectra were acquired in positive-ion mode (Tricin) and negative-ion mode (Coixol, Asperglaucide, and Amygdalin). The Q-TOF/MS was operated with capillary voltage 2.5 kV (negative ion) and 3 kV (positive ion), sample cone voltages 40 V, source temperature 120°C, desolvation temperature 500°C, desolvation gas flow of 1000 L/h, collision energy of 6 eV, full scan spectra from 50 to 1200 Da.

Health Examinations

Blood pressure and heart rate were measured using an electronic sphygmomanometer (Omron J710, Japan). Fasting peripheral blood samples were collected in vacuum tubes between 8:00 and 9:00 a.m. A noninvasive pulmonary function test was performed using a portable pulmonary function testing machine (MSA99, Beijing M&B Electronic Instruments Co., Ltd. China). Lung function measurements included the vital capacity (VC), FVC, FEV1.0, peak expiratory flow (PEF), MMEF, and forced expiratory flow between 25 and 75% of the FVC (FEF25%, FEF50%, FEF75%). The lung function parameter values were expressed as percent predicted using the estimated prediction value. RVD was defined as FVC <80% predicted and FEV1.0/FVC <0.70 (Kim et al., 2015). Two certified nurses completed all the clinical examinations at the university hospital. In addition, we collected data on key individual characteristics, including height and weight during the follow-ups, and the body mass index (BMI) was then calculated. All measurements were performed in a quiet room. Induced sputum was collected and processed as described by Pavord (Pavord et al., 1997). The GIMAS dying assay (Baso Diagnostics Inc., Zhuhai, China) was used to ascertain the proportion of lung inflammatory cells (monocyte-macrophages, neutrophils, eosinophils, and lymphocytes) in the induced sputum. We counted at least 200 lung inflammatory cells under an oil microscope and calculated the percentage of all cell types.

PM2.5 Exposure Assessment

We obtained real-time concentrations of ambient PM2.5 using the AirCasting Air Monitor (New York Hall of Science, USA), a portable personal environmental dust monitor. All devices were calibrated externally through an aerosol monitoring meter (pDR-1500, Thermal Scientific, China), and the following equation was used to calculate the PM2.5 concentrations:

\[ X = 10^{\text{Predicted Value}} \]

Statistical Analyses

The distribution of the lung function parameters and PM2.5 concentrations were tested using the Kolmogorov–Smirnov test. The variables with normal and non-normal distributions were calculated and described as mean ± standard deviation (SD) and median (interquartile range), respectively. Pearson’s chi-square test and the t-test were used to assess the differences between the placebo and QJWJ groups. To test the correlation between PM2.5 and lung function, Pearson’s correlation coefficient (Pearson’s r) was calculated. To derive the potential lagged effects of PM2.5 on lung function, multiple averaging periods were applied preceding the lung function measured, that is, lag 0 weeks (7 days before examination day), lag 1 week (from the eighth to the 14th day before examination), and lag 0–1 week (14 days before the examination day). In all analyses, statistical significance was set at two-tailed P-values < 0.05.

RESULTS

Demographic Characteristics

A total of 70 participants were screened, and 66 were enrolled and underwent randomization (33 were assigned to the QJWJ group, and
33 were assigned to the placebo group). One participant was excluded because no biological specimens were provided at the beginning of the study. Sixty-five participants (32 from the QJWJ group and 33 from the placebo group) completed the scheduled follow-ups (Figure 1). The height, weight, BMI, body temperature, heart rate, blood pressure, systolic blood pressure, and diastolic blood pressure did not differ between the two groups at baseline (Table 1). Routine blood test markers were analyzed in each health examination to evaluate the safety of QJWJ, and there was no statistically significant difference in blood biomarkers between the two groups at baseline or at the end of the trial (Supplementary Table S2 in the Supplementary Appendix S1).

PM$_{2.5}$ Concentrations Monitoring
Figure 2 shows the concentration of PM$_{2.5}$ at different periods of the study. The participants' average concentration of PM$_{2.5}$ exposure was 63.49 ± 44.08 µg/m$^3$, slightly lower than the level of the monitoring site (80.17 ± 47.13 µg/m$^3$). There was no significant difference in the daily and weekly averages of PM$_{2.5}$ between the two groups during the study period (Figures 2A,B). The average exposure concentration of PM$_{2.5}$ at lag 0 weeks was 79.71 ± 15.47 µg/m$^3$, 86.46 ± 15.99 µg/m$^3$ at lag 1 week, and 82.82 ± 14.66 µg/m$^3$ at lag 0–1 week (Supplementary Table S3).

Major Chemical Active Components of QJWJ
To demonstrate the major components of QJWJ granules, the UPLC-Q-TOF/MS analysis was performed and the total HPLC profile of QJWJ attained was shown in Supplementary Figure S2–S5. According to MS spectrum and retention times of UPLC-Q-TOF/MS analysis, peaks of QJWJ were tentatively identified as Coixol (Supplementary Figure S2), Asperglaucide (Supplementary Figure S3), and Amygdalin (Supplementary Figure S4) in negative ion mode, Tricin (Supplementary Figure S5) in positive ion mode. Taken together, the major chemical active components of QJWJ were Coixol, Asperglaucide, Amygdalin, and Tricin, which were consistent with previous studies (Gao et al., 2009; Fan et al., 2015; Wang et al., 2020; Li et al., 2021).

Correlation of RVD With PM$_{2.5}$ Concentrations Worldwide
We collected the data on the prevalence of RVD in different countries from the literature. The BOLD study reported that the incidence of RVD is 16.4% worldwide (Mannino et al., 2012). It varied widely across different countries, ranging between 8.5 and 46.1% (Soriano et al., 2012; Lee et al., 2015; Godfrey and Jankowich, 2016). Our study found that the incidence of RVD was 23.1% among the participants (Figure 3A). We also found a positive correlation between the global national annual mean PM$_{2.5}$ concentration and the incidence of RVD (Figure 3B).

Effects of QJWJ Administration on RVD Rate
The proportion of RVD was 21% in the placebo group and 25% in the QJWJ group at baseline. There were no other differences

| TABLE 1 | Characteristics of the participants at baseline. |
|--------------------------------------------------|
| Characteristics | Placebo group (N = 33) | QJWJ Group (N = 32) | t Value | P value |
|------------------|------------------------|---------------------|---------|---------|
| Height (cm, Mean ± SD) | 164.94 ± 6.82 | 161.84 ± 5.74 | 1.978 | 0.052 |
| Weight (kg, Mean ± SD) | 55.91 ± 6.69 | 55.28 ± 7.34 | 0.361 | 0.720 |
| BMI (kg/m$^2$, Mean ± SD) | 20.51 ± 1.87 | 21.09 ± 2.27 | 1.179 | 0.243 |
| Body temperature (°C, Mean ± SD) | 36.39 ± 0.30 | 36.48 ± 0.26 | 1.343 | 0.184 |
| Heart rate (bpm, Mean ± SD) | 78.09 ± 11.34 | 78.09 ± 11.34 | 0.452 | 0.624 |
| SBP (mmHg, Mean ± SD) | 105.15 ± 12.42 | 108.28 ± 9.05 | 1.158 | 0.251 |
| DBP (mmHg, Mean ± SD) | 71.45 ± 8.97 | 72.41 ± 6.34 | 0.493 | 0.624 |

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; QJWJ, qianjinweijing; SBP, systolic blood pressure; SD, standard deviation.
between the two groups. The percentage decreased to 6.2% after QJWJ administration for 2 weeks. Moreover, The RVD of all the participants returned to normal at the end of the QJWJ intervention, which was significantly different from the placebo group ($P = 0.018$) (Table 2).

### Correlation of Lung Function Parameters With PM$_{2.5}$ Concentrations

Lung function was primarily examined by VC, FVC, FEV$_{1.0}$, MMEF, PEF, FEF$_{25}$, FEF$_{50}$, and FEF$_{75}$. VC, PEF, and FEF$_{75}$, but not other indexes, were negatively correlated with PM$_{2.5}$ exposure at lag 0 weeks before the intervention. VC, FEV$_{1.0}$, PEF, FEF$_{25}$, and FEF$_{50}$ were negatively correlated with PM$_{2.5}$ exposure at lag 1 week before the intervention. However, the significantly negative correlation between lung function parameters and PM$_{2.5}$ exposure concentrations diminished at different time points after 2 and 4 weeks of QJWJ intervention (Table 3).

### Effects of QJWJ on Lung Function

We compared the levels of the lung function parameters between the two groups. No lung function parameter was significantly different between the QJWJ and placebo groups at either the baseline or follow-up time points. However, compared to the baseline before QJWJ intervention, QJWJ administration significantly increased the FVC and FEV$_{1.0}$ at the follow-ups (Table 4).

### Effects of QJWJ on Inflammatory Cell Proportion in the Induced Sputum

As showed in Table 5, the proportion of eosinophils in the QJWJ-induced sputum was 1.55%, which was significantly lower than that in the placebo group (2.58%). However, there was no significant difference in the proportions of the monocytes/macrophages, neutrophils, and lymphocytes between the two groups.

### DISCUSSION

In this trial, we investigated the effects of QJWJ on PM$_{2.5}$-related lung function decline at different time points. Our findings were as follows: 1) Compared with the placebo group, QJWJ intervention markedly alleviated the lung RVD; 2) PM$_{2.5}$ concentration was negatively correlated with VC, FEV$_{1.0}$, PEF, FEF$_{25}$, FEF$_{50}$, and FEF$_{75}$ with a lagging effect; 3) QJWJ intervention improved most of lung function parameters and diminished the association between PM$_{2.5}$ concentration and impaired lung function; 4) QJWJ reduced the proportion of eosinophils in the induced sputum.

RVD was a key symptom of lung disorders, and was common in adults worldwide. It was associated with increased morbidity and mortality due to impaired lung function (Lee et al., 2015; Godfrey and Jankowich, 2016). Based on data from the literature, air pollution is critically associated with RVD. The prevalence of RVD in the present study was 23.1%, higher than the global level. The reason for the high incidence of RVD may be the poor air quality in Shijiazhuang City (Zhang et al., 2016). Furthermore, most participants in the present study were female, who may have been more susceptible and demonstrated a higher prevalence of RVD (Godfrey and Jankowich, 2016).
TABLE 3 | Correlation between lung function indicators and individual dose of inhaled PM$_{2.5}$ at different periods.

| Lung function (%) | Before intervention | After 2 weeks QJWJ intervention | After 4 weeks QJWJ intervention |
|-------------------|---------------------|-------------------------------|-------------------------------|
| Lag 0 Week        | Lag 1 Week          | Lag 0–1 Week                  | Lag 0 Week                    | Lag 1 Week                    | Lag 0–1 Week                  |
| VC                | -0.246*             | 0.033                         | -0.003                        | -0.111                        | -0.117                        |
| FVC               | -0.073              | 0.191                         | 0.142                         | 0.074                         | 0.078                         |
| FEV$_{1.0}$       | -0.217              | -0.074                        | 0.365*                        | 0.224                         | 0.237                         |
| MMEF              | -0.188              | 0.093                         | 0.340                         | 0.135                         | 0.160                         |
| PEF               | -0.405*             | 0.053                         | 0.316                         | 0.110                         | 0.150                         |
| FEF$_{75}$        | -0.423*             | -0.107                        | 0.367*                        | 0.145                         | 0.192                         |
| FEF$_{50}$        | -0.159              | -0.012                        | 0.196                         | 0.039                         | 0.034                         |
| FEF$_{25}$        | 0.053               | -0.049                        | 0.080                         | 0.015                         | 0.005                         |

Abbreviations: VC, vital capacity; FVC, forced vital capacity; FEV$_{1.0}$, forced expiratory volume in 1 s; FEF$_{75}$, forced expiratory flow at 25% of the FVC; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow. *p < 0.05.

TABLE 4 | The difference of lung function parameters between groups in different periods.

| Lung Function | Baseline | Second follow | Finally follow |
|---------------|----------|---------------|---------------|
|                | Placebo group | QJWJ group | Placebo group | QJWJ group | Placebo group | QJWJ group |
| VC (%), Mean ± SD | 84.10 ± 8.42 | 80.75 ± 9.82 | 82.10 ± 9.57 | 83.44 ± 9.35 | 84.89 ± 10.15 | 86.93 ± 8.38* |
| FVC (%), Mean ± SD | 88.20 ± 8.39 | 85.24 ± 8.42 | 88.99 ± 8.65 | 89.43 ± 5.49* | 88.09 ± 9.55 | 90.40 ± 7.45* |
| FEV$_{1.0}$ (%), Mean ± SD | 95.72 ± 13.55 | 94.36 ± 13.41 | 94.41 ± 22.61 | 97.22 ± 16.45 | 91.21 ± 8.58 | 91.06 ± 9.25* |
| MMEF (%), Mean ± SD | 88.84 ± 13.33 | 84.63 ± 12.59 | 84.58 ± 20.03 | 85.07 ± 15.62 | 85.62 ± 22.06 | 95.61 ± 15.66 |
| PEF (%), Mean ± SD | 92.33 ± 14.15 | 88.66 ± 13.71 | 89.38 ± 21.26 | 88.64 ± 17.1 | 89.51 ± 16.77 | 90.71 ± 14.98 |
| FEF$_{75}$ (%), Mean ± SD | 102.09 ± 15.11 | 102.74 ± 17.30 | 105.07 ± 23.93 | 103.05 ± 16.87 | 106.77 ± 23.09 | 105.20 ± 17.54 |
| FEF$_{50}$ (%), Mean ± SD | 124.15 ± 36.02 | 121.04 ± 19.78 | 120.95 ± 24.81 | 120.95 ± 24.81 | 124.87 ± 32.7 | 118.58 ± 25.50 |

*Compared with baseline in the QJWJ group. p < 0.05.

Abbreviations: VC, vital capacity; FVC, forced vital capacity; FEV$_{1.0}$, forced expiratory volume in 1 s; FEF$_{25}$, forced expiratory flow at 25%; FEF$_{50}$, forced expiratory flow at 50% of FVC; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.

TABLE 5 | Induced sputum cell proportion between the two groups.

| Cell      | Placebo group | QJWJ group | t value | P value |
|-----------|---------------|------------|---------|---------|
| Mean      | Mean ± SD     | Mean ± SD  |         |         |
| Mono (%)  | 46.94 ± 13.18 | 48.34 ± 10.81 | 0.246 | 0.809  |
| Neut (%)  | 43.37 ± 13.84 | 45.36 ± 10.20 | 0.348 | 0.733  |
| Eo (%)    | 2.58 ± 0.74   | 1.55 ± 0.84  | 2.775 | 0.014* |
| Lymph (%) | 7.11 ± 2.31   | 4.75 ± 2.68  | 2.00  | 0.063  |

Abbreviations: Eo, eosinophils; Lymph, lymphocytes; Mono, monocytes/macrophages; Neut, neutrophils.

Numerous studies have illustrated that lung function decline is closely related to both short and long-term exposure to ambient PM$_{2.5}$, which increases the risk of respiratory disease (Guo et al., 2019; Tasmin et al., 2019). PEF, FVC, and FEV$_{1.0}$ were the most common parameters for the evaluation of lung function (Xu et al., 2020). PEF was frequently used to evaluate airway obstruction. MMEF, FEF$_{75}$, FEF$_{50}$, and FEF$_{25}$ are small airway function parameters, which are critical in small airway disease development and were seldom measured previously. In this study, we used a portable personal environmental dust monitor to assess the real-time individual PM$_{2.5}$ concentrations exposure. We observed a negative correlation between PM$_{2.5}$ concentrations and lung function (VC, PEF, and FEF$_{75}$).

Although the results only showed weak correlations between PM$_{2.5}$ concentration and lung function, we inferred that PM$_{2.5}$ inhalation was associated with a reduction in lung function. Further, we also analyzed the correlations between lung functions and PM$_{2.5}$ exposure at different time points. The results showed that VC, FEV$_{1.0}$, PEF, FEF$_{75}$, and FEF$_{50}$ were significantly correlated with average PM$_{2.5}$ exposure concentrations of lag 1 week. These results were consistent with other studies that showed that PM$_{2.5}$ has a substantial lag effect on population health (Xu et al., 2018; Hsu et al., 2020; Yang et al., 2020).

QJWJ, a classic Chinese prescription with a long history, could alleviate adverse effects in patients with lung disease. It has been used as an adjuvant medicine to treat lobar pneumonia (an acute attack in chronic bronchitis), chronic obstructive lung disease, allergic cough, and acute suppurrative tonsillitis. The QJWJ decoction was extracted from traditional Chinese herbs, including *Phragmites australis* (Cav.) Trin. ex Steud. [Poaceae], *Coix lacryma-jobi var. ma-yuen* (Rom.Caill.) Stapf [Poaceae], *Prunus persica* (L.) Batsch [Rosaceae], and *Benincasa hispida* (Thunb.) Cogn [Cucurbitaceae], which was effective in mitigating cough and phlegm (Liu et al., 2017). *Phragmites australis* (Cav.) Trin. ex Steud [Poaceae] exhibits anti-inflammatory activity by inhibiting NF-κB activation.
**CONCLUSION**

In conclusion, QJWJ could alleviate lung RVD and protect against PM$_{2.5}$-induced lung function decline. It is a potential intervention for air pollution-related respiratory disease.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Hebei Medical University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

RC wrote this manuscript. JZ, YP, QL, JP, XL, and WG conducted this study. RC, JZ, and WG analyzed and interpreted the patient data and PM$_{2.5}$ exposure data. JZ, YP, and QL performed the health examinations. LZ, RL, QS, RZ, and CL designed the study and made suggestions for the writing of this manuscript. RZ and CL were the correspondents of this manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (grant number 82004143 and 81973001), Key R&D International Cooperation Projects (grant number 2019YFE0114500), Medical Health Science and Technology Project of Zhejiang Province (grant number 2018KY545), and the Natural Science Foundation of Zhejiang Province (grant number Q18H260001).

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge all the volunteers who participated in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.873055/full#supplementary-material
REFERENCES

Chen, R., Zhao, A., Chen, H., Zhao, Z., Cai, J., Wang, C., et al. (2015). Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: a Randomized, Double-Blind Crossover Trial of Air Purifiers. J. Am. Coll. Cardiol. 65, 2279–2287. doi:10.1016/j.jacc.2015.03.553

Duprez, D. A., and Jacobs, D. R. (2018). Lung Function Decline and Increased Cardiovascular Risk. J. Am. Coll. Cardiol. 72, 1123–1125. doi:10.1016/j.jacc.2018.07.015

Falcon-Rodriguez, C. I., Osornio-Vargas, A. R., Sada-Ovalle, L., and Segura-Medina, P. (2016). Aerosol particles, Composition, and Lung Diseases. Front. Immunol. 7, 3. doi:10.3389/fimmu.2016.00003

Fan, Q., Zhang, P., Ren, M., and Pharmacy, D. (2015). Research Progress on Constituents from the Rhizomas of Phragmites Communis. Chin. J. Nat. Med. 7, 196–198. doi:10.3724/sj.1001.2009.00196

GBD Chronic Respiratory Diseases Collaborators (2020). Prevalence and Attributable Health Burden of Chronic Respiratory Diseases, 1990-2017: a Systematic Analysis for the Global Burden of Disease Study 2017. Lancet 391, 585–596. doi:10.1016/S0140-6736(20)30105-3

GBD Risk Factor Collaborators (2018). Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: a Systematic Analysis for the Global Burden of Disease Study 2017. Lancet 392, 1923–1994. doi:10.1016/S0140-6736(18)32225-6

Godfrey, M. S., and Jankovich, M. D. (2016). The Vital Capacity Is Vital: Epidemiology and Clinical Significance of the Restrictive Spirometry Pattern. Chest 149, 238–251. doi:10.1378/chest.15-1045

Guo, C., Hoek, G., Chang, L. Y., Bo, Y., Lin, C., Huang, B., et al. (2019). Long-Term Exposure to Ambient Fine Particulate Matter (PM2.5) and Lung Function in Children, Adolescents, and Young Adults: A Longitudinal Cohort Study. Environ. Health Perspect. 127, 127008. doi:10.1289/EHP5220

He, M., ichinose, T., Yoshida, S., Ito, T., He, C., Yoshida, Y., et al. (2017). PM2.5-induced Lung Inflammation in Mice: Differences of Inflammatory Response in Macrophages and Type II Alveolar Cells. J. Appl. Toxicol. 37, 1203–1218. doi:10.1002/jat.3482

Hsu, S. C., Chang, J. H., Lee, C. L., Huang, W. C., Hsu, Y. P., Liu, C. T., et al. (2020). Differential Time-Lag Effects of Ambient PM2.5 and PM2.5-bound PAHs on Asthma Emergency Department Visits. Environ. Sci. Pollut. Res. Int. 27, 43117–43124. doi:10.1007/s11356-020-12243-7

Hu, Y., Zhou, Q., Liu, T., and Liu, Z. (2020). Coixol Suppresses NF-kB-Mediated Signaling through Inhibition of NF-KB Pathway. Inflammation 39, 727–734. doi:10.1016/j.inflammm.2015.0299-6

Pavord, I. D., Pizzichini, M. M., Pizzichini, E., and Hargreave, F. E. (1997). The Use of Induced Sputum to Investigate Airway Inflammation. Thorax 52, 498–501. doi:10.1136/thx.52.6.498

Rapaka, D., Bitra, V., Ummidi, R., and Akula, A. (2021). Benincasa Hispida Alleviates Amyloid Pathology by Inhibition of Keap1/Nrf2-axis: Emphasis on Oxidative and Inflammatory Stress Involved in Alzheimer’s Disease Model. Neuropeptides 88, 102151. doi:10.1016/j.nepep.2021.102151

Sasano, J., Miravilles, M., Garcia-Rio, F., Munoz, L., Sanchez, G., Sobradiil, V., et al. (2012). Spirometrically-defined Restrictive Ventilatory Defect: Population Variability and Individual Determinants. Prim. Care Respi. J. 21, 187–193. doi:10.1016/j.pcrj.2010.02.0027

Tasnim, S., Ng, C. F. S., Stickley, A., Md N., Sarooz, G., Yasumoto, S., et al. (2019). Effects of Short-Term Exposure to Ambient Particulate Matter on the Lung Function of School Children in Dhaka, Bangladesh. Epidemilog 30 (1), S15–S23. doi:10.1097/EDE.00000000000001012

Wang, Y., Jia, Q., Zhang, Y., Wei, J., and Liu, P. (2020). Amygdalin Attenuates Atherosclerosis and Plays an Anti-inflammatory Role in ApoE Knock-Out Mice and Bone Marrow-Derived Macrophages. Front. Pharmacol. 11, 590929. doi:10.3389/fphar.2020.590929

Xing, Y., Xu, Y., Shi, M., and Lian, Y. (2016). The Impact of PM2.5 on the Human Respiratory System. J. Thorac. Dis. 8, 669–E74. doi:10.7752/jtd.2017.0243.2016.0119

Xu, D., Chen, Y., Wu, L., He, S., Xu, P., Zhang, Y., et al. (2020). Acute Effects of Ambient PM2.5 on Lung Function Among Schoolchildren. Sci. Rep. 10, 4061. doi:10.1038/s41598-020-61003-4

Xu, D., Zhang, Y., Zhou, L., and Li, T. (2018). Acute Effects of PM2.5 on Lung Function Parameters in Schoolchildren in Nanjing, China: a Panel Study. Environ. Sci. Pollut. Res. Int. 25, 14989–14995. doi:10.1007/s11356-018-1693-z

Yang, H. Y., Chang, H. K., and Lee, J. W. (2007). Amygdalin Suppresses Lipopolysaccharideinduced Expressions of Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in Mouse BV2 Microglial Cells. Neurol. Res. 29 (1), S59–S64. doi:10.1179/1616410X72248
Yang, X. Y., Wen, B., Han, F., Wang, C., Zhang, S. P., Wang, J., et al. (2020). Acute Effects of Individual Exposure to Fine Particulate Matter on Pulmonary Function in Schoolchildren. Biomed. Environ. Sci. 33, 647–659. doi:10.3967/bes2020.086

Yue, W., Tong, L., Liu, X., Weng, X., Chen, X., Wang, D., et al. (2019). Short Term Pm2.5 Exposure Caused a Robust Lung Inflammation, Vascular Remodeling, and Exacerbated Transition from Left Ventricular Failure to Right Ventricular Hypertrophy. Redox Biol. 22, 101161. doi:10.1016/j.redox.2019.101161

Zhang, L., Chen, R., and Lv, J. (2016). Spatial and Seasonal Variations of Polycyclic Aromatic Hydrocarbons (PAHs) in Ambient Particulate Matter (PM10, PM2.5) in Three Mega-Cities in China and Identification of Major Contributing Source Types. Bull. Environ. Contam. Toxicol. 96, 827–832. doi:10.1007/s00128-016-1810-y

Zhu, Z., Wu, H., Su, W., Shi, R., Li, P., Liao, Y., et al. (2019). Effects of Total Flavonoids from Exocarpium Citri Grandis on Air Pollution Particle-Induced Pulmonary Inflammation and Oxidative Stress in Mice. J. Food Sci. 84, 3843–3849. doi:10.1111/1750-3841.14966

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Zhang, Pang, Liu, Peng, Lin, Cao, Gu, Zhang, Li, Sun, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.